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Abstract
Intracranial mesenchymal tumors with FET-CREB fusions are a recently
described group of neoplasms in children and young adults characterized by
fusion of a FET family gene (usually EWSR1, but rarely FUS) to a CREB family transcription factor (ATF1, CREB1, or CREM), and have been variously
termed intracranial angiomatoid fibrous histiocytoma or intracranial myxoid
mesenchymal tumor. The clinical outcomes, histologic features, and genomic
landscape are not well defined. Here, we studied 20 patients with intracranial
mesenchymal tumors proven to harbor FET-CREB fusion by next-generation
sequencing (NGS). The 16 female and four male patients had a median age of
14 years (range 4–70). Tumors were uniformly extra-axial or intraventricular
and located at the cerebral convexities (n = 7), falx (2), lateral ventricles (4), tentorium (2), cerebellopontine angle (4), and spinal cord (1). NGS demonstrated
that eight tumors harbored EWSR1-ATF1 fusion, seven had EWSR1-CREB1,
four had EWSR1-CREM, and one had FUS-CREM. Tumors were uniformly
well circumscribed and typically contrast enhancing with solid and cystic
growth. Tumors with EWSR1-CREB1 fusions more often featured stellate/
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spindle cell morphology, mucin-rich stroma, and hemangioma-like vasculature
compared to tumors with EWSR1-ATF1 fusions that most often featured sheets
of epithelioid cells with mucin-poor collagenous stroma. These tumors demonstrated polyphenotypic immunoprofiles with frequent positivity for desmin,
EMA, CD99, MUC4, and synaptophysin, but absence of SSTR2A, myogenin,
and HMB45 expression. There was a propensity for local recurrence with a
median progression-free survival of 12 months and a median overall survival
of greater than 60 months, with three patients succumbing to disease (all with
EWSR1-ATF1 fusions). In combination with prior case series, this study provides further insight into intracranial mesenchymal tumors with FET-CREB
fusion, which represent a distinct group of CNS tumors encompassing both intracranial myxoid mesenchymal tumor and angiomatoid fibrous histiocytomalike neoplasms.
K EY WOR DS
angiomatoid fibrous histiocytoma (AFH), brain tumor, CREB, EWSR1, intracranial myxoid
mesenchymal tumor, molecular neuropathology, sarcoma
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I N T RODUC T ION

Intracranial mesenchymal tumors with FET-CREB fusions comprise a rare group of neoplasms of the central
nervous system (CNS) that have been variably described
as intracranial angiomatoid fibrous histiocytoma (AFH),
and more recently as intracranial myxoid mesenchymal
tumor (IMMT) (1–4). Despite their disparate names, intracranial AFH and IMMT are both molecularly defined
by in-frame gene fusions of the FET family of RNAbinding proteins (EWSR1 or FUS) to the CREB (cyclic
AMP response element-binding protein) family of transcription factors, which includes ATF1, CREB1, and
CREM. Notably, identical FET-CREB fusions are recurrently found in extracranial AFH, clear cell sarcoma of
soft tissue, clear cell sarcoma of the gastrointestinal tract,
primary pulmonary myxoid sarcoma, hyalinizing clear
cell carcinoma of the salivary gland, and a subset of malignant mesotheliomas lacking BAP1 and NF2 alterations
(5–15). However, the exact relation of these intracranial
mesenchymal tumors with FET-CREB fusions to extracranial AFH and other FET-CREB fusion-driven neoplasms remains unknown.
AFH has been characterized in the soft tissue as an
uncommon neoplasm of intermediate malignancy comprising 0.3% of all soft tissue tumors, most frequently
occurring in the subcutaneous tissue of the extremities

in children and young adults, but occasionally can be located within the viscera or retroperitoneum (5,14,16,17).
They display a characteristic histomorphology with four
defining characteristics, although not all are required for
diagnosis: solid nodules of epithelioid or spindled cells
with a syncytial growth pattern, pseudoangiomatous
spaces, a fibrous pseudocapsule, and robust pericapsular lymphoplasmacytic inflammatory infiltrates with
germinal center formation. AFH is well-described to display a spectrum of variant histomorphologies, such as
prominent myxoid stroma prompting some to describe
a myxoid variant of AFH (15,18–21). In one series, three
AFH with myxoid features occurring in the extremities
(two cases) or lung (one case) harbored EWSR1-CREM
fusions (15).
Several intracranial mesenchymal tumors histologically resembling AFH or the myxoid variant of AFH
and harboring FET-CREB fusions have now been reported (1–4,22–33). Kao et al first reported in 2017 four
children and young adults with intracranial myxoid
mesenchymal neoplasms with EWSR1-CREB1, EWSR1CREM, or EWSR1-ATF1 fusions (3). Shortly thereafter,
Bale et al reported three additional pediatric patients
with tumors composed of similar histologic features
and EWSR1-CREB1 or EWSR1-CREM fusions (1). The
authors postulated that these tumors may represent a
myxoid variant of AFH occurring intracranially, or
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alternatively a novel intracranial tumor entity (IMMT).
The reported cases of IMMT had mucin-rich stroma,
often lacked some of the characteristic histologic features of AFH, and were enriched for CREM fusions that
are rare in AFH of extracranial soft tissue. Despite some
morphologic similarities, they also have a spectrum of
morphologic appearances that partially overlap with
those of conventional AFH, including pseudo-encapsulation, nodular proliferations of epithelioid cells, and
prominent subcapsular lymphoplasmacytic aggregates
with hemosiderin deposition (1,3). The immunoprofiles
of both intracranial AFH-like tumors and IMMT are
similar to conventional AFH of extracranial soft tissue
(1–3). Tumor cells are consistently positive for desmin (at
least focally), but are negative for skeletal muscle markers including myogenin and MyoD1, as well as smooth
muscle markers including smooth muscle actin, caldesmon, and calponin. There is also positivity for CD99 and
EMA in the majority of tumors, while they are consistently negative for melanocytic markers (S100, HMB45)
and glial markers (GFAP and OLIG2). CD68 and CD163
have been positive in both neoplastic cells and tumor-associated macrophages. However, the clinical features,
patient outcomes, and optimal treatment strategies for
these tumors remain largely undefined.
Therefore, to further investigate the clinical, radiologic, and pathologic features of intracranial mesenchymal tumors with FET-CREB fusions, we have
comprehensively studied a cohort of 20 patients and reviewed the previously reported cases of these tumors in
the published literature.
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M AT E R I A L S A N D M ET HOD S

2.1 | Study population and tumor specimens
The study cohort consisted of 20 patients who underwent
surgical resection of a primary intracranial neoplasm
that was identified to harbor a gene fusion of EWSR1
or the related FUS together with a CREB family member (ATF1, CREB1, or CREM). Pathologic review of all
tumor specimens was performed by a group of expert
neuropathologists (E.A.S., A.P., and D.A.S.).

2.2 | Immunohistochemistry
Immunohistochemistry was performed on whole formalin-fixed, paraffin-embedded tissue sections using the
following antibodies: desmin (Cell Marque, clone D33,
undiluted, ER1 antigen retrieval), epithelial membrane
antigen (EMA, Leica, clone GP1.4, undiluted, ER1 antigen retrieval), CD99 (Signet, clone CD99, 1:400 dilution, ER1 antigen retrieval), S100 (DAKO, polyclonal,
1:2,000 dilution, no antigen retrieval), MUC4 (Millipore,
clone 8G7, 1:500 dilution, ER1 antigen retrieval),
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pan-neurotrophic receptor tyrosine kinase protein family (pan-NTRK, Abcam, clone EPR-17341, 1:100 dilution, ER2 antigen retrieval), somatostatin receptor 2A
(SSTR2A, Abcam, clone UMB1, 1:2,000 dilution, ER2
antigen retrieval), OLIG2 (Immuno Bio Labs, polyclonal,
1:200 dilution, ER1 antigen retrieval), glial fibrillary
acidic protein (GFAP, DAKO, polyclonal, 1:3,000 dilution, no antigen retrieval), synaptophysin (Cell Marque,
polyclonal, 1:100 dilution, ER2 antigen retrieval), CD68
(Leica, clone 514H12, undiluted, ER2 antigen retrieval),
cytokeratin AE1/AE3 (Dako, clone AE1/AE3, 1:100 dilution, ER1 antigen retrieval), cytokeratin CAM5.2
(Becton Dickinson, clone CAM5.2, 1:100 dilution, ER1
antigen retrieval), HMB45 (Dako, clone HMB45, undiluted, CC1 antigen retrieval), myogenin (Cell Marque,
clone F5D, undiluted, CC1 antigen retrieval), and Ki-67
(Dako, clone Mib1, 1:50 dilution, ER2 antigen retrieval).
Immunostaining for desmin, EMA, CD99, S100, MUC4,
pan-NTRK, SSTR2A, OLIG2, GFAP, synaptophysin,
CD68, cytokeratin AE1/AE3, cytokeratin CAM5.2, and
Ki-67 was performed in a Leica Bond-Max automated
stainer. Immunostaining for HMB45 and myogenin was
performed in a Ventana BenchMark Ultra-automated
stainer. Diaminobenzidine was used as the chromogen,
followed by hematoxylin counterstain.

2.3 | Targeted next-generation DNA
sequencing analysis
Tumor tissue was selectively scraped from unstained
slides or punched from formalin-fixed, paraffinembedded (FFPE) blocks using 2.0 mm disposable biopsy punches (Integra Miltex Instruments) to enrich for
as high tumor content as possible. Genomic DNA was
extracted from this macrodissected tumor tissue using
the QIAamp DNA FFPE Tissue Kit (Qiagen). Tumor tissue from both the initial surgical resection and a subsequent recurrence was sequenced for one patient (ATF1
#2). Capture-based next-generation DNA sequencing
was performed using an assay that targets all coding
exons of 479 cancer-related genes, select introns and upstream regulatory regions of 47 genes to enable detection
of structural variants including gene fusions, and DNA
segments at regular intervals along each chromosome to
enable genome-wide copy number and zygosity analysis,
with a total sequencing footprint of 2.8 Mb (UCSF500
Cancer Panel) (34). Multiplex library preparation was
performed using the KAPA Hyper Prep Kit (Roche)
according to the manufacturer's specifications. Hybrid
capture of pooled libraries was performed using a custom oligonucleotide library (NimbleGen SeqCap EZ
Choice). Captured libraries were sequenced as pairedend 100 bp reads on an Illumina HiSeq 2500 instrument.
Sequence reads were mapped to the reference human genome build GRCh37 (hg19) using the Burrows–Wheeler
aligner (BWA). Recalibration and deduplication of reads
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F I G U R E 1 Radiologic features of intracranial mesenchymal tumors with FET-CREB fusion. These tumors were typically contrast
enhancing and often demonstrated both solid and cystic components with extensive peritumoral edema

was performed using the Genome Analysis Toolkit
(GATK). Coverage and sequencing statistics were determined using Picard CalculateHsMetrics and Picard
CollectInsertSizeMetrics. Single nucleotide variant and
small insertion/deletion mutation calling was performed
with FreeBayes, Unified Genotyper, and Pindel. Large

insertion/deletion and structural alteration calling was
performed with Delly. Variant annotation was performed with ANNOVAR. Single nucleotide variants,
insertions/deletions, and structural variants were visualized and verified using Integrative Genome Viewer.
Genome-wide copy number and zygosity analysis was

2 of 21
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F I G U R E 2 Chromosomal copy number analysis demonstrates that EWSR1-ATF1 and EWSR1-CREB1 fusions typically result from
balanced translocations, whereas EWSR1-CREM fusions typically result from unbalanced translocations

performed by CNVkit and visualized using Nexus Copy
Number (Biodiscovery).

2.4 | Reverse-transcription PCR
Total RNA was extracted from formalin-fixed paraffin-embedded tissue using the RNeasy FFPE Isolation
Kit (Qiagen). Reverse transcriptase-polymerase chain
reaction (RT-PCR) was performed using SuperScript
III One-Step RT-PCR System (Life Technologies) and
the following primers: FUS, 5′-TGGACAGCAGAACC
AGTACA-3′ and CREM, 5′-CAGTAGGAGCTCGGA
TCTGG-3′. RT-PCR products were resolved by agarose
gel by electrophoresis and Sanger sequenced using
BigDye terminator chemistry (Applied Biosystems) following standard techniques.

2.5 | Kaplan–Meier survival plots and
statistical analyses
Clinical outcomes were studied by Kaplan–Meier analysis using GraphPad Prism. The Kaplan–Meier survival
analysis stratified by extent of resection includes only

the 17 patients from this cohort with known extent of
resection. Additional Kaplan–Meier survival analyses
include the 20 patients from this cohort combined with
the 18 prior cases of intracranial mesenchymal tumors
with FET-CREB fusions reported in the literature.
p values were calculated by Log-rank (Mantel-Cox) test.
Statistical comparison of histologic features was performed by Mann–Whitney unpaired two-tailed t test
using GraphPad Prism.

3

|

R E SU LT S

3.1 | Clinical features
The 16 female and four male patients had a median age
of 14 years (range 4–70 years) (Table 1). Two of the patients had a known history of prior neoplasia. Patient
CREB1 #3 had a history of pre-B acute lymphoblastic
leukemia at 10 years of age (7 years prior to the diagnosis of intracranial mesenchymal tumor with EWSR1CREB1 fusion), for which he received treatment with
prednisone and methotrexate but no radiation therapy.
Patient CREB1 #7 had a history of high-risk adrenal
neuroblastoma for which he received local radiation
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F I G U R E 3 Histologic features of intracranial mesenchymal tumors with FET-CREB fusion. Those tumors with EWSR1-ATF1 fusion were
most often composed of sheets of epithelioid to rhabdoid cells in a mucin-poor collagenous stroma. Those tumors with EWSR1-CREB1 or
EWSR1-CREM fusions were most often composed of cords and clusters of stellate to spindle cells in a mucin-rich stroma

treatment and systemic chemotherapy, but the posterior fossa where the intracranial mesenchymal tumor
with EWSR1-CREB1 fusion developed 5 years later
was outside the radiation treatment field. None of the
patients had a known tumor predisposition syndrome
or other known predisposing factors to neoplasia, and
none of the patients had evidence of extracranial neoplasms at time of diagnosis to suggest the possibility of
metastatic disease. Presenting symptoms were variable
and most frequently included severe headaches or nausea, and also occasionally seizures, tinnitus, or diplopia (Table S1).

3.2 | Radiologic features
Tumors were exclusively extra-axial in the meninges with
compression of the subjacent brain parenchyma or intraventricular, with locations at the cerebral convexities
(n = 7), falx (2), lateral ventricles (4), tentorium (2), cerebellopontine angle (4), and spinal cord (1). Radiologic
characteristics include circumscribed and lobulated
growth, often with both solid and cystic components,
avid enhancement after contrast administration, intratumoral blood products, and substantial peritumoral
edema (Figure 1). Some tumors showed a dural tail or

2 of 21
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F I G U R E 4 Specific histologic features recurrently observed in intracranial mesenchymal tumors with FET-CREB fusion. Example
illustrations are shown of the characteristic histologic features recurrently observed across all fusion types (e.g., collagenous stroma,
lymphoplasmacytic cuffing) and those enriched in specific fusion types (e.g., epithelioid/rhabdoid cell morphology with EWSR1-ATF1 fusion;
mucin-rich stroma, stellate/spindle cell morphology, and hemangioma-like vasculature with EWSR1-CREB1 fusion)

bony involvement of the overlying skull mimicking meningioma. One patient (ATF1 #7) demonstrated a mass
in the cerebellopontine (CP) angle with diffuse leptomeningeal dissemination along the spinal cord, whereas all
other patients had localized disease without dissemination at time of presentation.

3.3 | Genomic features
Next-generation sequencing (NGS) revealed that eight
tumors harbored EWSR1-ATF1 fusion, seven had
EWSR1-CREB1 fusion, four had EWSR1-CREM fusion, and one had FUS-CREM fusion. The fusions

INTRACRANIAL MESENCHYMAL TUMOR WITH FET-CREB FUSION

FIGURE 4.
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(Continued)

linked the 5′ coding exons of either EWSR1 or FUS to
the 3′ coding exons of ATF1, CREB1, or CREM. The
predicted fusion transcript most commonly linked exons
1–8 of EWSR1 to exons 5–7 of ATF1, 7–9 of CREB1, and
7–8 of CREM (Table S2). No likely pathogenic single nucleotide variants or indels were identified in any of the 20
tumors. Specifically, no TERT promoter hotspots mutations were present. No mutations or other alterations in
genes known to be recurrently altered in meningiomas

were identified (e.g., NF2, TRAF7, KLF4, AKT1, SMO,
PIK3CA, SMARCB1, BAP1, and YAP1) (35,36). All tumors lacked STAT6 rearrangements that are defining of
solitary fibrous tumor/hemangiopericytoma, and lacked
PAX3/7-FOXO1 fusions that characterize most alveolar
rhabdomyosarcomas (37,38).
Many of the tumors demonstrated a diploid genome
(n = 10), whereas the remaining demonstrated a paucity
of chromosomal gains or losses (Table S3). All of the

2 of 21
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tumors with either EWSR1-ATF1 or EWSR1-CREB1
fusion appear to have resulted from balanced translocations with an absence of copy number breakpoints at
chromosomes 22q12, 12q13, or 2q33 where these three
genes are located (Figure 2). In contrast, all five tumors
with either EWSR1-CREM or FUS-CREM fusion appear to have resulted from unbalanced translocations
(Figure 2). Recurrent loss of distal 10p with a breakpoint occurring at the CREM locus at 10p11 was seen
in all five tumors, accompanied by either loss of distal
22q with a breakpoint occurring at the EWSR1 locus at
22q12, or gain of distal 16p with a breakpoint at the FUS
locus at 16p11.

3.4 | Histologic features
The intracranial mesenchymal tumors with FET-CREB
fusion in this series demonstrated a wide morphologic
spectrum with several recurrent histologic features, some
of which were observed among tumors with all fusion
types and some of which were enriched in tumors with
specific fusion types (Figures 3 and 4, and Table 2). A
unifying feature of all tumors was a collagenous stroma
with dense intercellular matrix, as highlighted by reticulin
staining. A subset of tumors also demonstrated fibrous
septa separating nodules of tumor cells. The background
stroma ranged from mucin-rich, to collagenous, to nearly
absent. Tumor cell morphology included epithelioid/rhabdoid cells, stellate/spindle cells, and round cells (less frequent). In most cases, the stellate/spindle cell morphology

TA BL E 2

Histologic features of intracranial mesenchymal tumors with FET-CREB fusions

Histologic feature
a

All tumors

EWSR1-ATF1

EWSR1-CREB1 EWSR1-CREM FUS-CREM

12/20 (60%)

3/8 (38%)

7/7 (100%)

2/4 (50%)

0/1 (0%)

Collageneous stroma - intercellular
matrix

20/20 (100%)

8/8 (100%)

7/7 (100%)

4/4(100%)

1/1 (100%)

Collagenous stroma - internodular
septae

14/20 (70%)

4/8 (50%)

6/7 (86%)

3/4 (75%)

1/1 (100%)

Epithelioid/rhabdoid morphologya

10/20 (50%)

7/8 (88%)

1/7 (14%)

1/4 (25%)

1/1 (100%)

p = 0.01

10/20 (50%)

1/8 (13%)

7/7 (100%)

2/4 (50%)

0/1 (0%)

p = 0.001

2/20 (10%)

1/8 (13%)

0/7 (0%)

1/4 (25%)

0/1 (0%)

Hemangioma-like vasculaturea

10/20 (50%)

2/8 (25%)

6/7 (86%)

2/4 (50%)

0/1 (0%)

Staghorn/HPC-like vasculature

4/20 (20%)

1/8 (13%)

1/7 (14%)

2/4 (50%)

0/1 (0%)

Pseudoangiomatoid vasculature

0/20 (0%)

0/8 (0%)

0/7 (0%)

0/4 (0%)

0/1 (0%)

Dense lymphoplasmacytic cuffing

12/20 (60%)

4/8 (50%)

6/7 (86%)

1/4 (25%)

1/1 (100%)

Hemosiderin/hematoidin

13/20 (65%)

3/8 (38%)

6/7 (86%)

3/4 (75%)

1/1 (100%)

Meningioma-like whorls

4/20 (20%)

3/8 (38%)

0/7 (0%)

1/4 (25%)

0/1 (0%)

Amianthoid fibers

2/20 (10%)

1/8 (13%)

1/7 (14%)

0/4 (0%)

0/1 (0%)

Necrosis

2/20 (10%)

1/8 (13%)

0/7 (0%)

1/4 (25%)

0/1 (0%)

Mucin-rich stroma

Stellate/spindle cell morphology

a

Round cell morphology

a

occurred in those tumors with a mucin-rich stroma, but
occasional tumors were also seen with epithelioid morphology and a mucin-rich stroma histologically mimicking chordoid meningioma (Figure 5). Mitotic activity was
generally low, typically less than 5 mitoses per 1 mm2.
Dense lymphoplasmacytic cuffing at the tumor periphery
or along fibrous septa and evidence of prior intratumoral
hemorrhage with hemosiderin or hematoidin were seen in
the majority of cases. Hemangioma-like collections of dilated thin-walled vessels were a frequent finding, whereas
staghorn-like branching vessels characteristic of solitary
fibrous tumor/hemangiopericytoma were infrequent.
Blood-filled pseudoangiomatous spaces characteristic of
AFH occurring in extracranial soft tissue were not observed. Cellular whorls resembling those of meningioma
were observed in a subset. Necrosis was not a common
feature but was observed in two tumors. Most tumors
demonstrated relatively monotonous round or ovoid
nuclei, but two of the tumors (CREB1 #5 and FUS #1)
demonstrated increased nuclear pleomorphism and cytologic atypia. Tumor CREB1 #5 with EWSR1-CREB1 fusion was predominantly composed of stellate/spindle cells
in a mucin-rich stroma with abrupt transition to hypercellular foci of cytologically atypical and mitotically active
cells lacking a myxoid stroma. Tumor FUS #1 with FUSCREM fusion was composed of dense sheets of epithelioid to rhabdoid cells with striking cytologic atypia and
mitotic activity diffusely throughout the tumor (Figure 6).
When comparing histologic features versus specific fusion type, four histologic features were significantly enriched in specific fusion types (Table 2).

p = 0.03

p = 0.04

Denotes histologic features which are (bold values) statistically significantly different (p < 0.05) when comparing tumors with EWSR1-ATF1 fusion versus
EWSR1-CREB1 fusion via unpaired, non-parametric t-test (Mann-Whitney).
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Epithelioid or rhabdoid cell morphology was more
often observed in tumors with EWSR1-ATF1 fusion
versus EWSR1-CREB1 fusion ( p = 0.01). Conversely,
mucin-rich stroma, stellate/spindle cell morphology,
and hemangioma-like vasculature were more likely
to be observed in tumors with EWSR1-CREB1 fusion
versus EWSR1-ATF1 fusion ( p = 0.03, 0.001, and 0.04,
respectively).
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3.5 | Immunohistochemical features
All evaluated tumors in this cohort were positive for
desmin expression, which ranged from diffuse strong
labeling to limited focal clusters of tumor cells (Table 3
and Figure 7). The majority of cases were also positive
for EMA and CD99 in a membranous pattern. Variable
S100, synaptophysin, and CD68 immunostaining was

F I G U R E 5 Intracranial mesenchymal tumor with FET-CREB fusion can histologically mimic chordoid meningioma. Patient ATF1 #2 is a
9-year-old female who presented with an extra-axial mass along the cerebral convexity of the left frontal lobe. Surgical resection demonstrated
a neoplasm composed of cords and clusters of epithelioid cells in a mucin-rich stroma closely resembling chordoid meningioma. However, the
tumor was negative for SSTR2A expression and contained small foci of tumor cells with desmin expression. Genomic interrogation revealed
an in-frame EWSR1-ATF1 fusion and absence of mutations involving NF2 and other genes characteristic of meningioma

2 of 21
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also observed in a subset of tumors. Most tumors demonstrated no immunoreactivity for cytokeratins AE1/AE3
and CAM5.2, with only one tumor demonstrating focal

SLOAN et al.

labeling for AE1/AE3. MUC4 immunostaining was observed in five of seven evaluated tumors, which ranged
from diffuse strong labeling to focal clusters of positive

F I G U R E 6 Intracranial mesenchymal tumor with FUS-CREM fusion. A, A 4-year-old girl presented with fevers and headaches and was
found to have a large circumscribed and heterogeneously-enhancing mass in the left occipital region of the brain with significant peritumoral
edema. After gross total resection, local tumor recurrence was seen on follow-up imaging as multiple-enhancing nodules at the periphery of
the prior resection cavity. B, Histologic sections demonstrated a highly cellular neoplasm with both sheet-like and papillary growth patterns
composed of epithelioid to rhabdoid tumor cells with prominent nuclear pleomorphism and atypia. C, Chromosomal copy number plot
demonstrates that the FUS-CREM fusion was the result of an unbalanced translocation between chromosome 10p11.21 and chromosome
16p11.2. D, Schematic of the FUS-CREM gene fusion. E, Sanger chromatogram following reverse-transcription PCR of the FUS-CREM fusion
transcript composed of exons 1–5 of FUS linked with exons 7–8 of CREM
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cells. Pan-NTRK immunohistochemistry demonstrated
positivity in only one of five evaluated tumors. All evaluated tumors were negative for expression of glial fibrillary
acidic protein (GFAP), myogenin, somatostatin receptor 2A (SSTR2A), and HMB45. All tumors tested (n = 5)
had intact/retained expression of INI-1 (also referred to
BAF47 or SMARCB1). Reticulin staining demonstrated
abundant intercellular basement membrane deposition in
all evaluated tumors (n = 12). The Ki-67 labeling index
was generally low (less than 5%, seven of the 13 evaluated
tumors), but occasionally was elevated up to 15–20% (six
of the 13 evaluated tumors). There was no significant association of specific CREB fusion partner with distinct
immunophenotype or Ki-67 labeling index observed.

3.6 | Clinical outcomes
The complete clinical data including extent of resection, treatment regimen, and outcome data from the 20
patients are presented in Table 1 and Table S1. Nine
patients initially had a gross total resection, whereas
only a subtotal resection was achieved in eight patients.
Extent of resection was unknown in the remaining three
patients. None of the patients who had gross total resection were treated with adjuvant therapy, whereas five
of the eight patients who had subtotal resection were
treated with adjuvant radiation (n = 3), adjuvant chemotherapy (n = 1), or both radiation and chemotherapy
(n = 1). The chemotherapy regimens were both sarcomabased using ifosfamide together with vincristine and
doxorubicin or carboplatin and etoposide. Among the
19 patients with available clinical follow-up, 11 patients

T A B L E 3 Immunohistochemical
features of intracranial mesenchymal
tumors with FET-CREB fusions
Desmin
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(58%) experienced tumor recurrence/progression and
three patients (16%) died of disease, all of whom had
tumors with EWSR1-ATF1 fusion that were subtotally
resected. Kaplan–Meier analysis of overall survival and
progression-free survival stratified by extent of resection revealed that subtotal resection was associated with
increased risk of death and tumor recurrence, although
neither was statistically significant (Figure 8). Seven of
the nine patients (78%) with subtotal resection experienced local recurrence/progression within 12 months,
and one patient (ATF1 #6) developed metastatic disease
to the thoracic spine and lymph nodes. Kaplan–Meier
analysis of overall survival and progression-free survival
stratified by mucin-rich versus mucin-poor stroma revealed a possible trend toward improved outcomes for
those tumors with mucin-rich stroma, although this
was not statistically significant (Figure 9). Among the
12 cases with available clinical follow-up data that were
evaluated for Ki-67 labeling index, the subset of patients
with elevated tumor proliferative indices (greater than
5%) had increased frequency of recurrence (five of six
patients [83%]), whereas the subset of patients with low
tumor proliferative indices (less than 5%) had lower frequency of recurrence (three of six patients [50%]).
In order to further assess the clinical outcomes for
these tumors, we next curated clinical data from all reported cases of intracranial mesenchymal tumors with
confirmed FET-CREB fusions published in the scientific literature to date (Table 4). Patient age, sex, tumor
location, and survival data were analyzed from the 20
patients in our cohort together with these 18 previously reported patients (Figure 10). The median patient
age was 17 years (range 4–70 years) at time of initial

All tumors

EWSR1ATF1

EWSR1CREB1

EWSR1CREM

FUSCREM

16/16 (100%)

7/7 (100%)

6/6 (100%)

2/2 (100%)

1/1 (100%)

EMA

13/14 (93%)

5/5 (100%)

5/6 (83%)

2/2 (100%)

1/1 (100%)

CD99

10/11 (91%)

4/5 (80%)

4/4 (100%)

1/1 (100%)

1/1 (100%)

S100

5/12 (42%)

3/6 (50%)

2/5 (40%)

ND

0/1 (0%)

CD68

5/6 (100%)

1/1 (100%)

2/3 (100%)

1/1 (100%)

1/1 (100%)

MUC4

5/7 (71%)

3/5 (60%)

1/1 (100%)

1/1 (100%)

ND

pan-NTRK

1/5 (20%)

0/3 (0%)

1/1 (100%)

0/1 (0%)

ND

Synaptophysin

5/8 (63%)

1/2 (50%)

2/4 (50%)

1/1 (100%)

1/1 (100%)

GFAP

0/9 (0%)

0/1 (0%)

0/6 (0%)

0/1 (0%)

0/1 (0%)

Myogenin

0/6 (0%)

ND

0/4 (0%)

0/1 (0%)

0/1 (0%)

SSTR2a

0/8 (0%)

0/4 (0%)

0/3 (0%)

ND

0/1 (0%)

HMB45

0/6 (0%)

0/3 (0%)

0/2 (0%)

ND

0/1 (0%)

Cytokeratin
AE1/AE3

1/7 (17%)

1/2 (50%)

0/4 (0%)

0/1 (0%)

ND

Cytokeratin
CAM5.2

0/9 (0%)

0/2 (0%)

0/5 (0%)

0/1 (0%)

0/1 (0%)
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F I G U R E 7 Immunohistochemical features of intracranial mesenchymal tumors with FET-CREB fusion. These tumors were uniformly
positive for desmin expression, which ranged from diffuse strong labeling to cases with focal clusters of positive cells only. Most tumors were
also positive for EMA and CD99 expression in a membranous distribution. A subset of tumors demonstrated positivity for synaptophysin that
ranged from diffuse strong to more focal and weak staining. These tumors were uniformly negative for SSTR2A, GFAP, and HMB45. Most
tumors were negative for cytokeratin expression, with only a single tumor that demonstrated focal positivity for cytokeratin AE1/AE3 (not
shown)

diagnosis. These 38 patients included 12 males and 26
females. Tumors were located at the cerebral convexities (n = 14), falx (6), lateral ventricle (6), third ventricle

(1), skull base (1), CP angle (5), tentorium (3), and spinal
cord (1). No significant association of fusion type with
patient age or tumor location was apparent (Figure 10).

INTRACRANIAL MESENCHYMAL TUMOR WITH FET-CREB FUSION

F I G U R E 8 Clinical outcomes for patients with intracranial
mesenchymal tumors with FET-CREB fusion based on extent of
surgical resection. A, Kaplan–Meier plot of the overall survival for
the 17 patients from this study with known extent of resection. B,
Kaplan–Meier plot of progression-free survival for the 17 patients
from this study with known extent of resection. Compared to gross
total resection, subtotal resection was associated with increased risk
of death and tumor recurrence (although neither was statistically
significant)

Kaplan–Meier analysis for the 38 patients revealed a
median overall survival of greater than 60 months with
91% survival rate at 5 years (Figure 11A), and a median
progression-free survival of 28 months (Figure 11B).
Kaplan–Meier analysis of overall survival or progression-free survival stratified by fusion type did not identify a statistically significant difference in outcomes
(Figure 11C,D). However, three patients with tumors
containing EWSR1-ATF1 fusion succumbed to disease,
while all patients with EWSR1-CREB1 or EWSR1CREM fusion remained alive at time of last clinical
follow-up.

4
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DI SC US SION

Here, we have studied a cohort of 20 patients with intracranial mesenchymal tumors harboring FET-CREB
fusions, and comprehensively characterized their
radiologic, molecular, and clinicopathologic features.
Additionally, we have compiled and reviewed the 18
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previously reported cases of intracranial tumors demonstrated to have EWSR1 or FUS fused to a CREB family
gene. Our findings demonstrate that these tumors occur
with a female predominance (12 males/26 females) in a
wide age range (4–70 years old), but most often occur
in the second and third decades of life (median age of
17 years). They are predominantly extra-axial or intraventricular tumors which can arise throughout the
neuroaxis, including the falx, tentorium, cerebral convexities, skull base, spinal cord, lateral ventricle, and third
ventricle. They are typically contrast-enhancing masses,
well circumscribed with solid and cystic growth patterns,
and often have pronounced peritumoral edema. Of the 38
total tumors, 15 had EWSR1-ATF1 fusion, 13 EWSR1CREB1, 9 EWSR1-CREM, and 1 FUS-CREM. Beyond
the oncogenic fusions, no additional pathogenic mutations, amplifications, or deletions were identified in our
tumor cohort by a broad NGS panel of approximately
500 cancer-associated genes. Most of these tumors demonstrated a diploid or near-diploid genome with a paucity of chromosomal gains and losses. While all tumors
with EWSR1-ATF1 and EWSR1-CREB1 fusions were
the result of balanced translocations, all tumors with
EWSR1-CREM or FUS-CREM fusions demonstrated
intrachromosomal copy number breakpoints occurring
at the CREM and EWSR1 or FUS loci, indicative of unbalanced translocation as the mechanism of gene fusion.
The reason for this divergence in unbalanced versus balanced translocations for tumors with CREM as the fusion
partner versus those with ATF1 or CREB1 is uncertain.
Histologically, intracranial mesenchymal tumors
with FET-CREB fusions demonstrate a range of morphologic features that encompass both those previously
described in AFH and IMMT. We note that tumors
with CREB1 or CREM as the fusion partners are enriched for those with stellate/spindle cell morphology
and prominent myxoid stroma, and those with ATF1
are enriched for those with epithelioid morphology with
mucin-poor stroma. However, this was not always the
case, as we encountered tumors with EWSR1-CREB1
fusion and epithelioid morphology with mucin-poor
stroma, as well as tumors with EWSR1-ATF1 fusion
and stellate/spindle cell morphology with mucin-rich
stroma. Additionally, a subset of tumors contained
both of these morphologic patterns within the same resection specimen. No immunophenotypic differences
were noted when stratifying tumors by fusion type or
morphologic pattern.
In terms of clinical outcomes, these tumors demonstrate a propensity for local recurrence and occasionally dissemination or metastasis leading to mortality.
The available data suggest improved outcomes for patients that are able to undergo gross total resection.
The growth rates have been variable, and the interval
to disease recurrence has been up to 10 years. While
optimal treatment strategy remains to be defined,
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F I G U R E 9 Clinical outcomes for patients with intracranial mesenchymal tumors with FET-CREB fusion based on mucin content of the
stroma. A and B, Kaplan–Meier plot of overall survival (A) and progression-free survival (B) for the 20 patients from this study stratified by
mucin-rich versus mucin-poor stroma

adjuvant radiation may be a consideration given the
propensity for local recurrence, especially for incompletely resected tumors. Histologic features or other
criteria to predict disease course were not identified
by this study, although the three patients who died of
disease all had EWSR1-ATF1 fusions. Larger patient
cohorts are needed to define prognostic criteria for
these neoplasms.
These intracranial mesenchymal tumors with FETCREB fusion can both radiographically and histologically mimic a number of other intracranial tumor
entities. The extra-axial location and dural tail seen
radiologically in a subset of tumors can result in a preoperative impression of meningioma or solitary fibrous
tumor/hemangiopericytoma. Microscopically, these tumors can feature syncytial growth and meningioma-like
whorls that closely resemble meningioma. Additionally,
those with rhabdoid cytology, or with cords of epithelioid cells in a mucin-rich stroma, could be misinterpreted as rhabdoid or chordoid variants of meningioma
(Figure 4). The frequent expression of EMA in these
tumors can further confound the differential diagnosis
of meningioma. Fortunately, these tumors are negative

for SSTR2A and positive for desmin, which can be
used to distinguish them immunohistochemically.
Furthermore, FET-CREB fusions are specific to these
tumors and are not found in meningiomas, and all the 19
tumors analyzed by next-generation sequencing in this
study lacked meningioma-associated mutations in NF2,
TRAF7, KLF4, SMO, AKT1, PIK3CA, and BAP1. The
extra-axial location and prominent collagenous stroma
can also raise the diagnostic possibility of solitary fibrous tumor/hemangiopericytoma. However, intracranial mesenchymal tumors with FET-CREB fusions lack
nuclear STAT6 immunopositivity and the characteristic
NAB2-STAT6 fusion. They are desmin positive, but lack
expression of skeletal muscle markers including myogenin and MyoD1 that allows distinction from rhabdomyosarcoma. They uniformly have intact expression of
INI1 and lack SMARCB1 mutations or deletions, which
distinguishes them from atypical teratoid/rhabdoid
tumor and proximal-type epithelioid sarcoma. A subset
of these tumors demonstrates MUC4 immunopositivity,
a protein marker previously thought to be highly specific
to low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, tumor entities which are defined
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F I G U R E 1 0 Anatomic location and age at diagnosis for intracranial mesenchymal tumors with FET-CREB fusion from this study
combined with all previously reported cases in the literature (see Table 4). A, Plot of patient age at diagnosis versus gene fusion. B, Diagram of
tumor locations. C. Plot of tumor location versus gene fusion

by fusion of FUS (or rarely EWSR1) to either CREB3L1
or CREB3L2. The subset of tumors with round cell
morphology, collagenous stroma, and polyphenotypic
differentiation by immunohistochemistry with the combination of desmin, EMA, and synaptophysin positivity overlaps with desmoplastic small round cell tumor
(DSRCT), which do rarely occur intracranially (39).
Fluorescence in situ hybridization showing EWSR1
break-apart does not allow distinction between DSRCT
with EWSR1-WT1 fusions and those intracranial mesenchymal tumors with EWSR1 fusions to CREB family
members. Therefore, the distinction from DSRCT requires additional testing to determine the specific fusion
partner. The possibility of a brain metastasis from a primary extracranial tumor should be considered as part
of the workup of these patients, although all of these
tumors described to date have appeared to be primary
intracranial neoplasms. Noteworthy is that these intracranial mesenchymal tumors with FET-CREB fusion
are negative for expression of melanocytic markers such
as HMB45 and MITF that is characteristic of clear cell
sarcoma of soft tissue, and are almost always positive
for desmin expression which is absent in both clear cell
sarcoma of soft tissue and primary pulmonary myxoid
sarcoma (11,13).

Because of the overlapping histologic, immunophenotypic, and molecular features of IMMT and intracranial
AFH-like neoplasms, there has been ongoing uncertainty
as to whether these tumors represent two distinct entities,
versus a single entity defined by intracranial location and
FET-CREB fusions (1,3). The overlapping histologic spectrum seen across these tumors with different fusion types
(and even within the same tumor) suggests that intracranial AFH and IMMT may likely represent morphologic
variants of a single biologic tumor entity. In support of
this, the clinical outcome data did not show significant
differences in overall or progression-free survival when
stratified by fusion type or mucin-rich versus mucin-poor
stroma.
In summary, we have characterized a group of intracranial tumors with FET-CREB fusions, which to date
have been categorized as either intracranial AFH or
IMMT. Further investigation including epigenetic profiling is needed to define the true nature of these unique
intracranial neoplasms and their exact relationship to
extracranial tumors with similar fusions. Future studies are also needed to explore the relationships between
patient outcomes and additional clinicopathologic variables such tumor location, extent of resection, fusion
type, and morphologic features.
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F I G U R E 1 1 Clinical outcomes for patients with intracranial mesenchymal tumors with FET-CREB fusion from this study combined with
all previously reported cases in the literature (see Table 4). A, Kaplan–Meier plot of overall survival demonstrates a median overall survival
>60 months. B, Kaplan–Meier plot of progression-free survival demonstrates that a majority of patients experience disease recurrence with a
median interval of 28 months. C, Kaplan–Meier plot of overall survival stratified by fusion type. While no statistically significant difference in
overall survival based on fusion type is observed, three patients with tumors containing EWSR1-ATF1 fusion succumbed to disease, while all
patients with EWSR1-CREB1 or EWSR1-CREM fusion remained alive at time of last clinical follow-up. D, Kaplan–Meier plot of progressionfree survival stratified by fusion type. No significant difference was observed based on fusion type (median recurrence-free survival: EWSR1ATF1, 16 months; EWRS1-CREB1, 49 months; EWSR1-CREM, 28 months)
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